Incyte Corporation

NasdaqGS:INCY Stock Report

Market Cap: US$12.1b

Incyte Past Earnings Performance

Past criteria checks 1/6

Incyte has been growing earnings at an average annual rate of 14.3%, while the Biotechs industry saw earnings growing at 22.7% annually. Revenues have been growing at an average rate of 12.3% per year. Incyte's return on equity is 0.9%, and it has net margins of 0.8%.

Key information

14.3%

Earnings growth rate

14.2%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate12.3%
Return on equity0.9%
Net Margin0.8%
Last Earnings Update31 Dec 2024

Recent past performance updates

Recent updates

Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib

Mar 18

Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025

Feb 11

Incyte: Multiple Drug Launches Bode Well For Future Growth

Jan 11

Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff

Oct 31

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Aug 19

Incyte: The Worst Has Been Avoided

Jun 16

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Jun 06
It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

May 07
We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

May 03
Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Apr 26

Incyte: A Potential GARP Superstar

Feb 27

Knight's affiliate files for Brazilian approval of cancer drug tafasitamab

Oct 07

Revenue & Expenses Breakdown

How Incyte makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:INCY Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 244,241331,239161
30 Sep 244,076321,2070
30 Jun 243,857971,1650
31 Mar 243,7687451,1430
31 Dec 233,6965981,159127
30 Sep 233,6094251,1380
30 Jun 233,5133661,1360
31 Mar 233,4703241,1050
31 Dec 223,395341999113
30 Sep 223,3318769540
30 Jun 223,3209458790
31 Mar 223,1159337960
31 Dec 212,9869497410
30 Sep 212,9135356820
30 Jun 212,7213386120
31 Mar 212,7034785610
31 Dec 202,667-2965180
30 Sep 202,457-3354870
30 Jun 202,388-1914690
31 Mar 202,229-3764570
31 Dec 192,1594474690
30 Sep 192,1084054410
30 Jun 192,0063064350
31 Mar 191,9972534370
31 Dec 181,8821094350
30 Sep 181,798-1094240
30 Jun 181,729-1024190
31 Mar 181,534-1674010
31 Dec 171,536-3133670
30 Sep 171,419-1553630
30 Jun 171,306-1543480
31 Mar 171,226-1073240
31 Dec 161,1061043020
30 Sep 161,0231512600
30 Jun 16941742310
31 Mar 16858492160
31 Dec 1575471970
30 Sep 15634-861930
30 Jun 15644131840
31 Mar 15581-331740
31 Dec 14511-481660
30 Sep 14485-541550
30 Jun 14372-1361420
31 Mar 14374-1011250

Quality Earnings: INCY has a large one-off gain of $96.2M impacting its last 12 months of financial results to 31st December, 2024.

Growing Profit Margin: INCY's current net profit margins (0.8%) are lower than last year (16.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: INCY's earnings have grown by 14.3% per year over the past 5 years.

Accelerating Growth: INCY's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: INCY had negative earnings growth (-94.5%) over the past year, making it difficult to compare to the Biotechs industry average (40.2%).

Return on Equity

High ROE: INCY's Return on Equity (0.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/25 21:38
End of Day Share Price 2025/03/25 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Incyte Corporation is covered by 51 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Thomas RussoBaird
Ishan MajumdarBaptista Research